- Dozens missing, 9 dead in migrant boat wreck off Spanish Canaries
- Death toll from Hurricane John hits eight in Mexico
- Storm Helene's toll rises as rescue and cleanup efforts gain pace
- SpaceX launches mission to return stranded astronauts
- Storm Helene kills 44, threatens more 'catastrophic' flooding as cleanup begins
- SpaceX set to launch mission to return stranded astronauts
- Storm Helene kills 44, threatens more 'catastrophic' flooding
- Boeing strike grinds on as latest talks fail to reach agreement
- Iran 'news' sites, hackers target Trump ahead of US election
- US ports brace for potential dockworkers strike
- Japan's speedy, spotless Shinkansen bullet trains turn 60
- US hurricane deaths rise to 44, fears of more 'catastrophic' flooding
- Global stocks mostly rise, cheering Beijing stimulus
- Europe en route for Moon with new simulator, says astronaut Pesquet
- Fireworks forecast if comet survives risky Sun flypast
- Argentina judge orders dictionary to delete pejorative definition of 'Jewish'
- Global stocks rise on rate hopes, Beijing stimulus
- S.African woman turns 118, among the oldest in the world
- UK clears $4 bn AI partnership between Amazon, Anthropic
- Barca fans barred from Champions League away game over racist banner
- Chinese stocks extend surge, Europe higher on Beijing stimulus
- Pope says Church must 'seek forgiveness' for child sexual abuse
- China caps week of 'bazooka' stimulus for ailing economy with rate cut
- Cuts, cash, credit: China bids to jumpstart flagging economy
- France's debt weighs heavier ahead of budget debate
- Iran treads carefully, backing Hezbollah while avoiding war
- Return to sender: waste stranded at sea stirs toxic dispute
- 'Broken' news industry faces uncertain future
- On remote Greek island, migratory birds offer climate clues
- Taken from mother by nuns, victim seeks answers as pope visits Belgium
- China cuts amount banks hold in reserve to boost lending
- Hong Kong, Shanghai extend surge as China optimism boosts markets
- Vietnam president reiterates support for Cuba during official visit
- Drought reduces Amazon River in Colombia by as much as 90%: report
- Stay or go? Pacific Islanders face climate's grim choice
- Florida bracing for 'unsurvivable' Hurricane Helene
- Poverty rises to over 52 percent in Milei's Argentina
- Chloe's see-through look may not be for Kamala Harris
- Champagne houses abuzz over English sparkling wine
- Macron, Trudeau pledge to work for 'decarbonized' economies
- Hurricanes, storms, typhoons... Is September wetter than usual?
- China stimulus, tech optimism boost stock markets
- 'Unsurvivable' Hurricane Helene races towards Florida
- Macron meets Trudeau in Canada as both face political setbacks
- South Korea surges in UN innovation index
- Chloe's see-through look may not be for Kamala
- Floods threaten Niger's historic 'gateway to the desert'
- China economy hopes boost global equities
- Ubisoft shares sink after 'Assassin's Creed' delay
- German economy to shrink again in 2024: think tanks
Astra warns on falling Covid treatment sales after record year
British Covid vaccine maker AstraZeneca on Thursday warned that coronavirus product sales and profit margins would drop this year as the pandemic recedes and after record-high group revenue in 2021.
AstraZeneca rapidly developed a successful Covid-19 jab during the pandemic that generated full-year sales of almost $4.0 billion (3.5 billion euros) last year, the company said in a results statement.
After initially offering the vaccine at cost, Astra decided in November to begin selling Vaxzevria -- developed alongside University of Oxford -- for profit.
- Covid revenue decline -
Revenue from Covid-19 medicines is set to decline by up to a quarter, AstraZeneca said Thursday.
But total group revenues would increase this year by a "high-teens percentage" thanks in part to sales of antibody treatment Evusheld.
The drug is for high-risk people who show resistance to vaccines against coronavirus.
Astra on Thursday added that its net profit tumbled last year, hit by costs arising from the vast takeover of US biotech firm Alexion.
Profit after tax slumped to $112 million (98 million euros) from $3.2 billion in 2020.
Revenues soared 41 percent to $37.4 billion.
"2021 was an exceptional year for AstraZeneca in terms of revenue, which exceeded $37 billion and was the highest in the company's history," noted chief executive Pascal Soriot.
"This put us well on track to deliver our promise of annual revenue of $40 billion one year ahead of schedule."
He added that AstraZeneca's "rapidly improving financial position" had allowed it to raise its annual dividend payment the first time in a decade.
Soriot said the company last year delivered on its "promise of broad and equitable access" to its Covid-19 vaccine" with 2.5 billion doses released for supply around the world".
At the same time, the group faced vast costs following its $39-billion takeover of Alexion, while large impairment and restructuring charges also weighed.
Astra swung into a pre-tax annual loss of $265 million, after a $3.9-billion profit last time around.
But its share price was up 2.1 percent in London trading Thursday.
"The Covid vaccine has raised Astra's global profile significantly," said Hargreaves Lansdown analyst Keith Bowman.
"For now, and with further innovation and new drug successes ongoing, analyst consensus opinion continues to point to a strong buy" of its shares.
Since taking the helm at AstraZeneca in 2012, Soriot has pushed the company into lucrative treatments such as cancer therapies, and the Alexion takeover gives it more heft in areas such as treating blood disorders.
As for its Covid vaccine, "time spent developing and distributing (the jab)... has been time away from its core business", Bowman added.
"The purchase of Alexion at what is considered a full price is also yet to be fully justified."
Astra's EU's Covid vaccination roll-out was extremely sluggish initially because of a big shortfall in the amount of doses the company had promised the bloc, sparking a row between the parties.
The European Union has since pivoted towards mRNA vaccines, particularly the one produced by US drugs giant Pfizer in partnership with German peer BioNTech, after rare blood-clot problems with AstraZeneca increased public hesitancy about taking it.
D.Avraham--CPN